Medicina Galassia Assimilazione gepotidacin clinical trials carta geografica Eleganza vittoria
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants | SpringerLink
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants | SpringerLink
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Antibiotics | Free Full-Text | Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia—An In Vitro and In Vivo Study
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea | Sexually Transmitted Infections
How to Treat Urinary Tract Infections (UTI): GSK's Gepotidacin May Work - Bloomberg
TITLE PAGE
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Novel drug gepotidacin for uncomplicated UTI meets trial goals
Gepotidacin: New antibiotic appears to be effective against UTIs, company says | CNN
Overview of microbiome dynamics during gepotidacin Phase 2a clinical... | Download Scientific Diagram
New Antibiotic for Urinary-Tract Infections Found Effective in Trials - WSJ
Antibiotics | Free Full-Text | Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges
GSK initiates Phase III programme of gepotidacin antibiotic
TITLE PAGE
GSK stops two Phase 3 studies for gepotidacin stopped early
Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects - Tiffany - 2022 - Clinical and Translational Science - Wiley Online Library
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants | Antimicrobial Agents and Chemotherapy
First Novel Antibiotic Since 20 Years, Gepotidacin Debuts To Treat Drug Resistance Urinary Tract Infections (UTIs) Amidst Growing Incidences! - Thailand Medical News
Gepotidacin for Urinary Tract Infection Clinical Trial 2023 | Power
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy